FDA Approves Pemgarda to Protect High-Risk Patients From Covid
Monday, 25 March 2024, 21:31
FDA Approves Pemgarda Drug for High-Risk Covid Patients
Pemgarda, the newly authorized drug by the FDA, is designed to protect high-risk individuals from Covid. This drug specifically targets immunocompromised patients who may not mount an adequate response to vaccination.
Key Points:
- Pemgarda: A novel drug approved by the FDA.
- Target Population: Immunocompromised individuals at high risk for Covid.
- Availability: Expected to be accessible in the following weeks.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.